B-cell lymphoma 2 (Bcl-2) as an anti-apoptotic protein has a central role in regulating cell death and survival.1 Altered Bcl-2 biology has been implicated in a large number of cancer cells, including B-cell lymphomas like diffuse large B-cell lymphoma (DL-BCL) and chronic lymphocytic leukemia (CLL).2, 3, 4 In many cases, Bcl-2 is upregulated, increasing the resistance of the cancer cell toward pro-apoptotic signals like oncogenic stress or genomic instability and thus promoting their survival.5, 6. This evidence concerns the gene BCL2 and B-cell chronic lymphocytic leukemia.